OncoMatch/Clinical Trials/NCT03300492
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Is NCT03300492 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for acute myeloid leukemia.
The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS. Haplo-HSCT is a preferred treatment option for patients with AML or MDS without a HLA-matched donor. With administration of cyclophosphamide post-transplant , the safety of the procedure is similar to a HSCT from a HLA-identical donor. Relapse of AML/MDS represents a serious problem following haplo-HSCT. NK cells are immune cells able to destroy tumor cells. Their potency has been established particularly in the setting of a haplo-HSCT. In the current study, study participants undergoing haplo-HSCT will receive expanded NK cells from their respective stem-cell donors following haplo-HSCT. The primary goal of the study is to establish the safety and feasibility of this approach. In addition, the activity of the NK cells will be examined.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Lab requirements
Blood counts
adequate organ function as judged by transplant physicians
Kidney function
adequate organ function as judged by transplant physicians
Liver function
adequate organ function as judged by transplant physicians
Cardiac function
adequate organ function as judged by transplant physicians
Judged by the transplant physicians to have adequate organ function and no contraindications to haplo-HSCT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify